Few repurposed drugs have generated as much public attention—or as much controversy—as ivermectin. To some, it represents a promising but overlooked cancer therapy. To others, it has become a symbol of medical misinformation. The reality is considerably more nuanced. Ivermectin has an extraordinary history as one of the world’s most successful antiparasitic medications, and the laboratory research investigating its potential anticancer effects is both extensive and scientifically interesting. At the same time, the evidence demonstrating meaningful benefit in cancer patients remains limited.

Understanding why ivermectin has become such a controversial topic requires separating two very different questions. The first is whether the drug can influence cancer cells under experimental conditions. The second is whether those findings translate into improved outcomes for people with cancer. Those questions are related, but they are not the same.

A Drug That Changed Global Medicine

Ivermectin was discovered during a collaboration between Japanese microbiologist Satoshi Ōmura and Irish-born parasitologist William C. Campbell in the late 1970s. Ōmura isolated a previously unknown species of Streptomyces bacteria from soil samples collected in Japan. Campbell, working at Merck, recognized that compounds produced by the microorganism possessed remarkable antiparasitic activity. Further refinement led to ivermectin, a derivative of avermectin that proved extraordinarily effective against a variety of parasitic diseases.

Its impact on global health was profound.

Before ivermectin became widely available, diseases such as river blindness (onchocerciasis) and lymphatic filariasis affected millions of people throughout Africa, Latin America, and parts of Asia. Through international donation programs and mass drug-administration campaigns, ivermectin dramatically reduced the burden of these diseases and helped move several countries toward elimination. Over the following decades, billions of doses were administered worldwide, making ivermectin one of the most extensively used antiparasitic medications in medical history.

In recognition of this achievement, Campbell and Ōmura were awarded the 2015 Nobel Prize in Physiology or Medicine for discoveries concerning a novel therapy against infections caused by roundworm parasites.

That Nobel Prize was awarded for ivermectin’s proven effectiveness against parasitic disease—not for cancer—but the drug’s remarkable clinical history encouraged researchers to ask whether it might possess useful biological properties beyond treating parasites.

Why Cancer Researchers Became Interested

Drug repurposing has become an increasingly important area of oncology because developing an entirely new cancer drug often requires well over a decade of research and billions of dollars in investment. Existing medications already have established manufacturing methods, known pharmacology, and well-characterized safety profiles within their approved uses, making them attractive candidates for investigation in new diseases.

As researchers began screening approved drugs against cancer cells, ivermectin repeatedly emerged as a compound capable of affecting tumor biology in laboratory models. Unlike traditional chemotherapy agents that often target a single pathway, ivermectin appeared to influence numerous biological processes associated with cancer growth.

Over the past decade, published laboratory studies have reported activity against models of breast, pancreatic, colorectal, ovarian, lung, liver, prostate, cervical, gastric, kidney, melanoma, brain cancers, and several hematologic malignancies. These findings do not demonstrate that ivermectin treats cancer in patients, but they explain why scientific interest has continued to grow despite limited clinical evidence.

Multiple Proposed Anticancer Mechanisms

One reason ivermectin has attracted sustained research attention is that no single mechanism appears to explain its laboratory activity.

Depending on the experimental model, investigators have reported effects on PAK1 signaling, WNT/β-catenin pathways, Akt/mTOR signaling, YAP1 activity, mitochondrial metabolism, autophagy, purinergic signaling, multidrug-resistance proteins such as P-glycoprotein, and components of the tumor immune microenvironment. Other studies have suggested that ivermectin may promote programmed cell death, interfere with cancer stem-cell survival, alter cellular energy production, or increase the susceptibility of tumor cells to immune attack.

The breadth of these reported mechanisms is scientifically intriguing, but it also illustrates an important point about cancer biology. Cancer is not a single disease, and tumors arising from different organs often depend on entirely different molecular pathways. A mechanism observed in leukemia cells may not occur in pancreatic cancer, and a pathway disrupted in mice may have far less importance in humans. Rather than proving a universal anticancer effect, these studies suggest multiple hypotheses that require independent testing.

Laboratory Success Does Not Guarantee Clinical Success

The transition from laboratory research to patient care is where most experimental cancer therapies fail.

Many ivermectin experiments expose cancer cells to micromolar drug concentrations for prolonged periods under tightly controlled laboratory conditions. Standard antiparasitic dosing in humans generally produces much lower circulating concentrations, and ivermectin is highly protein-bound in the bloodstream, reducing the amount of free drug available to interact with tissues. While tissue accumulation, altered formulations, or different dosing strategies might eventually change these pharmacokinetic limitations, whether therapeutically relevant concentrations can be achieved safely in human tumors remains an unresolved scientific question rather than an established fact.

This issue is not unique to ivermectin. It represents one of the most common reasons why compounds that appear highly effective in cell cultures ultimately fail during clinical development. Laboratory experiments identify biological possibilities; clinical trials determine whether those possibilities translate into meaningful patient benefit.

What Human Studies Have Found

Despite hundreds of laboratory publications, reliable human evidence remains surprisingly limited.

As of the research summarized in this article, no completed randomized clinical trial has demonstrated that ivermectin improves survival, slows disease progression, or consistently shrinks tumors in cancer patients. Most available human data consist of early-phase safety studies, observational reports, or isolated case reports rather than trials capable of establishing efficacy.

The principal prospective clinical investigation currently underway is a Phase I/II study evaluating ivermectin in combination with immune checkpoint inhibitors for metastatic triple-negative breast cancer. The trial is designed primarily to evaluate safety while exploring whether ivermectin might enhance responses to immunotherapy. Preliminary findings from the first small group of participants suggested that the combination appeared feasible from a safety standpoint, but the number of evaluable patients was far too small to determine whether ivermectin contributed meaningful anticancer activity. Without a control group receiving immunotherapy alone, any observed responses cannot be confidently attributed to ivermectin.

Another registered Phase II study had not yet begun recruiting during the period covered by this review. Registration of a clinical trial should be viewed as evidence that researchers intend to study a question—not as evidence that a treatment has already proven effective.

The Observational Study That Sparked Debate

One publication received considerable attention within the repurposed-drug community because it appeared to report favorable outcomes among cancer patients taking ivermectin together with mebendazole.

The study followed 197 patients treated through a telemedicine practice and reported encouraging clinical outcomes. Because it involved real patients rather than laboratory experiments, it was widely cited online as evidence that ivermectin had demonstrated effectiveness against cancer.

However, several important limitations substantially reduced the strength of those conclusions. The study lacked randomization, relied heavily on self-reported outcomes, included patients receiving concurrent cancer therapies, and had no untreated comparison group. These limitations alone prevent observational research from establishing causation. More significantly, the journal subsequently issued an Expression of Concern, formally notifying readers that questions had arisen regarding the publication. An Expression of Concern is not equivalent to a retraction, but it represents an important warning that confidence in the findings should be reduced until those concerns are resolved.

Publication Warnings on Influential Laboratory Research

A similar development affected one of ivermectin’s most frequently cited laboratory papers.

In 2021, investigators reported that ivermectin appeared to convert immunologically “cold” breast tumors into “hot” tumors in mouse models while enhancing responses to immune checkpoint blockade. Because immunotherapy has transformed treatment for several cancers, the possibility that an inexpensive existing drug could strengthen immune responses attracted widespread attention.

In June 2026, however, the journal issued an Editorial Expression of Concern regarding that publication. This action does not establish that the reported findings are incorrect, but it does indicate that the paper should no longer be treated as unqualified evidence supporting ivermectin’s anticancer potential. Any balanced review of the literature should acknowledge both the original findings and the subsequent editorial warning.

Safety Considerations

Ivermectin’s extensive history in treating parasitic infections often leads to the perception that it is inherently safe regardless of dose or indication. That conclusion is not supported by the available evidence.

Approved antiparasitic dosing has accumulated an extensive safety record over decades of clinical use. Cancer treatment, however, may require different doses, longer durations, different patient populations, or combinations with other medications that have never undergone comparable evaluation.

Recent case reports illustrate this distinction. One described life-threatening neurotoxicity in a patient who self-administered high-dose ivermectin while attempting to treat metastatic breast cancer. Another documented severe liver injury following combined veterinary fenbendazole and ivermectin use for prostate cancer. Individual case reports cannot establish how frequently such events occur, but they demonstrate that high-dose, off-label self-treatment should not automatically be assumed to carry the same safety profile as approved antiparasitic use.

Where the Evidence Stands Today

Ivermectin occupies an unusual position within cancer research.

Few repurposed drugs possess such an extensive laboratory literature or such a remarkable history as an established human medication. Researchers have identified numerous biologically plausible mechanisms, demonstrated activity in a wide range of experimental cancer models, and initiated early clinical trials to determine whether those findings can be translated into patient care.

At the same time, the evidence required to establish ivermectin as an effective cancer therapy has not yet been produced. Randomized clinical trials demonstrating improved survival or durable tumor responses are still lacking. Important observational findings have been weakened by methodological limitations and subsequent publication concerns, while one of the field’s most influential preclinical papers now carries an editorial expression of concern.

Taken together, the current evidence supports continued scientific investigation rather than definitive clinical conclusions. Ivermectin remains an intriguing research candidate whose laboratory promise has yet to be confirmed—or definitively refuted—in rigorous human cancer trials.

Fenbendazole: The Drug That Went Viral

If ivermectin is the most controversial drug in this discussion, fenbendazole is undoubtedly the most famous on social media. Unlike ivermectin, fenbendazole is not approved for human use. It is a veterinary antiparasitic medication commonly used to treat worms in dogs, horses, cattle, and other animals. Its popularity in cancer circles began after the widely publicized story of Joe Tippens, who credited a combination of conventional cancer treatment and a fenbendazole-based regimen for his recovery. His story spread rapidly online, inspiring thousands of cancer patients to investigate the drug for themselves.

Like ivermectin, fenbendazole has attracted legitimate scientific interest. Laboratory studies have shown that it can interfere with microtubules—the structural components cells need to divide—and researchers have reported anticancer activity in several animal models. These findings provide a scientific rationale for continued research, but they do not demonstrate that the drug is an effective cancer treatment in humans. Despite years of public interest, no prospective interventional clinical trials evaluating fenbendazole as a cancer treatment in people have been identified.

Much of the public enthusiasm surrounding fenbendazole has been driven by testimonials rather than controlled clinical research. Personal stories can be compelling, particularly when they involve patients with advanced cancer who experience unexpected recoveries. However, they rarely provide enough information to determine why someone improved. Many patients receive surgery, chemotherapy, radiation, immunotherapy, or targeted drugs at the same time they begin alternative treatments. Without carefully designed clinical trials, it’s impossible to know whether the experimental therapy, conventional treatment, the natural course of the disease, or some combination of factors was responsible for the outcome.

This distinction is particularly important in the case of the Joe Tippens story. Tippens has consistently stated that he added fenbendazole while participating in conventional cancer treatment, including immunotherapy. His experience deserves to be reported accurately, but it should not be interpreted as proof that fenbendazole alone caused his remission. One patient’s experience, no matter how remarkable, cannot establish that a treatment works for others.

Adding to the uncertainty, one of the most frequently cited publications supporting fenbendazole was later retracted. The paper described three patients who reportedly experienced favorable outcomes after self-administering fenbendazole, but the journal formally withdrew the article in 2026. A retracted paper should not be cited as evidence that a treatment is effective. While the retraction does not prove that fenbendazole has no anticancer activity, it significantly weakens one of the most commonly referenced human reports used to support its use.

Safety is another area where caution is warranted. Because fenbendazole is not approved for human use, there are no established dosing guidelines for cancer patients. In recent years, physicians have published several case reports describing serious liver injury in people who self-treated with veterinary fenbendazole, sometimes in combination with ivermectin. These reports cannot determine how often such complications occur, but they demonstrate that the drug should not be assumed to be harmless simply because it belongs to the same chemical family as medications approved for humans.

At present, fenbendazole remains an interesting laboratory candidate rather than an established cancer therapy. The biological mechanisms being investigated are scientifically plausible, but the human evidence needed to determine whether those mechanisms translate into meaningful clinical benefit has not yet been produced. Until well-designed clinical trials are completed, claims that fenbendazole cures cancer—or that it has been proven ineffective—go beyond what the current evidence can support.

Mebendazole: The Strongest Human Evidence—But Still Early

Among the four drugs discussed in this article, mebendazole currently has the strongest body of human cancer research. Originally approved to treat parasitic worm infections in people, it has attracted the attention of cancer researchers because it interferes with microtubules—the same cellular structures targeted by several established chemotherapy drugs. That doesn’t mean mebendazole works like chemotherapy, but it does provide a biologically plausible reason to investigate whether it could have anticancer effects.

Unlike fenbendazole, mebendazole has progressed beyond laboratory studies and into early human clinical trials. Several Phase I studies in patients with high-grade gliomas demonstrated that the drug could be administered at doses much higher than those used to treat parasitic infections. These trials were designed primarily to evaluate safety, determine appropriate dosing, and measure how the drug behaved in the body—not to prove that it improved survival. Even so, the results were encouraging enough to justify additional research.

One of the most frequently cited human studies involved patients with newly diagnosed high-grade gliomas who received mebendazole in combination with the standard chemotherapy drug temozolomide. Researchers reported a median overall survival of approximately 21 months, but because every patient received standard treatment and there was no randomized control group, the study could not determine whether mebendazole was responsible for any improvement. Patients who remained on treatment longer also tended to live longer, but that observation may simply reflect the fact that healthier patients are able to continue therapy for longer periods. This type of bias is common in early-phase studies and is one reason randomized trials remain the gold standard for evaluating effectiveness.

Another small randomized study in patients with metastatic colorectal cancer reported improved response rates and longer progression-free survival when mebendazole was added to standard chemotherapy. While those findings generated optimism, the trial enrolled only 40 patients at a single center. Small studies can sometimes produce results that fail to hold up when repeated in larger populations, which is why independent replication is essential before changing clinical practice. At present, this remains one of the more promising findings in the field—but not a definitive answer.

Not all of the news has been positive. A Phase II study evaluating mebendazole in advanced gastrointestinal cancers was terminated after patients experienced disease progression despite treatment. Although the drug appeared to be reasonably well tolerated, the trial did not demonstrate meaningful clinical benefit. This serves as an important reminder that scientific progress depends on reporting both positive and negative findings. Looking only at favorable studies can create a misleading impression of how strong the evidence really is.

Taken together, the evidence suggests that mebendazole deserves continued investigation. It has advanced further into human cancer research than the other drugs discussed here, and there are legitimate reasons for scientific interest. At the same time, the available studies remain too small, too early, and too limited to conclude that mebendazole is an effective treatment for cancer. At present, it is best described as a promising research candidate rather than an established cancer therapy.

Albendazole: An Older Drug with Limited Human Research

Albendazole is another antiparasitic medication approved for use in humans, and like mebendazole, it belongs to the benzimidazole family of drugs. Researchers became interested in albendazole after laboratory studies suggested it could interfere with cancer cell growth by disrupting microtubules, reducing the formation of new blood vessels that feed tumors, and affecting several cellular signaling pathways. These findings were encouraging enough to justify early human studies, but the clinical evidence remains limited.

The first published human investigations were small pilot studies involving patients with advanced cancers who had exhausted standard treatment options. In one study of seven patients with liver and colorectal cancers, researchers observed decreases or stabilization in tumor markers in several participants. While these findings generated interest, tumor-marker changes alone cannot demonstrate that a treatment shrinks tumors or prolongs survival. More importantly, three patients developed severe neutropenia—a dangerous reduction in white blood cells—and the investigators concluded that the drug’s toxicity required careful monitoring.

A larger Phase I dose-escalation study involving 36 patients focused primarily on determining how much albendazole could be given safely. Researchers established a maximum tolerated dose and documented the drug’s pharmacology, providing valuable information for future studies. Some patients experienced substantial reductions in tumor markers, but once again, these were exploratory findings rather than proof of clinical benefit. The trial was not designed to determine whether albendazole improved survival or slowed disease progression, and it included no randomized comparison group.

Although albendazole has demonstrated enough activity to warrant scientific investigation, cancer research involving the drug has progressed much more slowly than many advocates expected. No large randomized clinical trials have established it as an effective cancer treatment, and most of the available human evidence still comes from early-stage safety studies rather than trials designed to measure effectiveness. That doesn’t mean the drug lacks potential—it simply means the evidence needed to answer that question has not yet been produced.

Today, albendazole occupies a middle ground. It has more human data than fenbendazole and some evidence supporting continued research, but considerably less clinical evidence than would be required before oncologists could recommend it as part of standard cancer care. As with the other drugs discussed in this article, the science remains a work in progress rather than a settled conclusion.

The Other Pieces of the Protocols: Looking Beyond the Antiparasitic Drugs

While ivermectin, fenbendazole, mebendazole, and albendazole receive most of the public attention, they are rarely promoted as standalone cancer treatments. Instead, they are usually presented as part of much larger protocols that combine repurposed medications, dietary interventions, vitamins, supplements, and metabolic therapies. Depending on the source, a protocol may include intravenous vitamin C, metformin, doxycycline, melatonin, low-dose naltrexone, curcumin, vitamin D, zinc, ketogenic diets, fasting, hyperbaric oxygen therapy, or numerous other interventions.

This creates an important problem when evaluating the evidence.

Even if several individual components appear scientifically promising, that does not automatically validate the combination. Drug interactions, timing, dosing, and patient selection all influence whether a combination therapy ultimately helps or harms patients. Cancer medicine is filled with examples of drugs that performed well individually but failed when combined—or combinations that worked only because one specific component contributed most of the benefit.

Most public cancer protocols blur those distinctions.

Rather than asking whether an entire regimen has been tested, they often present evidence for each ingredient separately. The result can give readers the impression that dozens of proven therapies have been assembled into a comprehensive treatment plan, when in reality the complete protocol itself has never undergone prospective clinical evaluation.

For that reason, each component deserves to be considered on its own merits.

Intravenous Vitamin C

Few complementary cancer therapies have generated as much scientific interest as intravenous vitamin C.

The concept dates back to the work of Nobel laureate Linus Pauling and surgeon Ewan Cameron during the 1970s, who proposed that high-dose vitamin C might improve survival in patients with advanced cancer. Subsequent randomized studies using oral vitamin C failed to reproduce those findings, leading many researchers to dismiss the approach.

Interest returned years later when investigators recognized that oral and intravenous vitamin C produce dramatically different blood concentrations.

At sufficiently high intravenous doses, vitamin C may act not only as an antioxidant but also as a pro-oxidant within the tumor microenvironment, generating hydrogen peroxide that some cancer cells appear less able to detoxify than healthy tissue. Laboratory and animal studies have demonstrated anticancer activity under certain conditions, and multiple early-phase clinical trials have explored intravenous vitamin C in combination with chemotherapy, radiation therapy, and immunotherapy.

Thus far, however, human evidence remains mixed.

Several Phase I and Phase II studies suggest that intravenous vitamin C can often be administered safely alongside standard cancer treatment, and some have reported encouraging signals in specific cancers. Others have found little or no measurable clinical benefit. No large randomized trial has established intravenous vitamin C as a standard anticancer therapy across cancer types.

This distinction is important because many public protocols describe intravenous vitamin C as though its effectiveness has already been demonstrated. The current evidence is more restrained. It remains an active area of oncology research, but definitive proof of improved survival has not yet been established.

Metformin

Metformin is one of the world’s most widely prescribed medications for type 2 diabetes and has become another leading candidate for drug repurposing.

Interest began after epidemiologic studies suggested that diabetic patients taking metformin sometimes appeared to experience lower rates of certain cancers than patients receiving other diabetic therapies. Laboratory experiments subsequently demonstrated that metformin can influence cellular metabolism, activate AMP-activated protein kinase (AMPK), inhibit mTOR signaling, reduce circulating insulin levels, and potentially alter the metabolic environment in which tumors grow.

These findings led to hundreds of observational studies and numerous clinical trials.

Despite the extensive research effort, the overall picture remains uncertain.

Some studies have suggested benefit in particular patient populations or tumor types, while others have found little difference once important confounding factors are accounted for. Several randomized trials have failed to demonstrate the broad anticancer effects that many early observational studies seemed to predict.

Today, most researchers view metformin as a biologically plausible adjunct worthy of continued investigation rather than an established cancer treatment. It illustrates how promising laboratory mechanisms and encouraging observational data do not necessarily translate into consistent clinical benefit.

Doxycycline

Doxycycline is best known as an antibiotic, but it has also attracted attention because of its effects on mitochondrial protein synthesis.

Some investigators have proposed that cancer stem cells may depend heavily on mitochondrial function and that doxycycline might selectively impair those cells under certain conditions. Laboratory studies have reported reductions in cancer stem-cell markers and increased sensitivity to chemotherapy in several experimental models.

Human evidence, however, remains limited.

Melatonin

Melatonin is commonly associated with sleep regulation, yet it also possesses antioxidant, anti-inflammatory, and immune-modulating properties that have made it a subject of cancer research for decades.

Laboratory studies suggest melatonin may influence tumor growth, angiogenesis, immune function, and responsiveness to chemotherapy or radiation therapy. Several small clinical studies have reported improvements in quality of life or reductions in certain treatment-related side effects, while others have explored whether melatonin might enhance responses to conventional therapy.

Although the overall safety profile of melatonin appears favorable when used appropriately, the evidence supporting direct anticancer effects remains inconsistent. Current research is sufficient to justify continued investigation but insufficient to establish melatonin as a proven anticancer treatment.

Low-Dose Naltrexone

Low-dose naltrexone (LDN) has become increasingly popular within integrative medicine.

Unlike standard doses used for opioid dependence, LDN is proposed to produce brief opioid receptor blockade that may subsequently increase endogenous endorphin production and influence immune function. Supporters argue that these immune effects could help the body recognize or suppress malignant cells.

At present, this hypothesis remains largely speculative.

Laboratory research and small pilot studies have generated interest, but robust randomized clinical evidence demonstrating meaningful anticancer benefit has not been established. Much of the enthusiasm surrounding LDN continues to arise from anecdotal reports rather than controlled oncology trials.

Curcumin

Curcumin, the principal bioactive compound in turmeric, is among the most extensively studied natural compounds in cancer research.

Laboratory experiments have demonstrated effects on inflammation, NF-κB signaling, apoptosis, angiogenesis, oxidative stress, and numerous additional pathways associated with cancer biology. Hundreds of publications describe potential anticancer mechanisms across a wide variety of tumor models.

The challenge has been translating these findings into patients.

Curcumin has notoriously poor oral bioavailability, and despite extensive efforts to develop improved formulations, many human studies remain small, heterogeneous, and difficult to interpret. While some early trials have reported encouraging biological effects or improvements in laboratory markers, convincing evidence that curcumin improves survival or consistently enhances standard cancer therapy remains lacking.

Ketogenic Diets and Fasting

Dietary interventions occupy a unique place in cancer research because they influence the body’s metabolism rather than directly targeting tumor cells.

The ketogenic diet attempts to shift energy metabolism toward ketone utilization while reducing glucose availability. Some researchers have proposed that certain tumors may be less adaptable to this metabolic shift than normal tissues.

Similarly, fasting and fasting-mimicking diets have been investigated as potential methods of increasing tumor sensitivity to chemotherapy while protecting healthy tissues from treatment-related toxicity.

Laboratory evidence supporting both approaches is substantial.

Human evidence, however, remains preliminary. Early clinical studies suggest these interventions may be feasible for selected patients under medical supervision, but definitive evidence demonstrating improved survival across cancers has not yet emerged. Nutritional interventions may also be inappropriate or even harmful for patients with advanced cancer who are already experiencing weight loss, cachexia, or malnutrition.

Hyperbaric Oxygen Therapy

Hyperbaric oxygen therapy has also been proposed as a complementary cancer treatment because many tumors contain poorly oxygenated regions that contribute to treatment resistance.

Increasing tissue oxygenation could theoretically enhance the effectiveness of radiation therapy or certain chemotherapy agents. Laboratory and animal studies have explored these possibilities for years.

Clinical evidence remains considerably less certain.

While hyperbaric oxygen has well-established medical uses for conditions such as radiation injury and difficult wound healing, its role as a direct anticancer therapy has not been established through large randomized oncology trials.

Vitamin D, Zinc, CBD, and Other Supplements

Numerous additional supplements appear in public cancer protocols.

Vitamin D deficiency has been associated with poorer outcomes in some observational studies, but correcting deficiency should not be confused with demonstrating that high-dose supplementation treats cancer.

Zinc plays important roles in immune function and cellular biology, yet evidence supporting supplemental zinc as an anticancer therapy remains limited.

Cannabidiol (CBD) has generated interest because of laboratory findings suggesting effects on inflammation, pain, anxiety, and tumor biology. Human oncology research has focused primarily on symptom management rather than demonstrating direct anticancer effects.

Nearly every protocol contains additional vitamins, minerals, botanical compounds, or metabolic therapies with varying degrees of scientific support. Some possess reasonable biological rationales. Others remain almost entirely theoretical. Few have undergone the type of rigorous testing necessary to determine whether they improve survival when added to modern cancer treatment.

The Central Problem with Combination Protocols

When viewed individually, many components of these protocols appear scientifically interesting. Some have laboratory evidence. Some have encouraging animal studies. Others have progressed into early human clinical trials.

What is missing is evidence for the entire combination.

A protocol containing ten ingredients is not supported simply because each ingredient has published research. Until the complete regimen is evaluated prospectively using clearly defined patient populations, appropriate comparison groups, standardized outcomes, and long-term follow-up, its overall effectiveness remains unknown.

This distinction is easy to overlook but fundamental to evidence-based medicine.

Individual components may ultimately prove beneficial, ineffective, or even harmful in combination. Only carefully designed clinical research can determine which is true. Until those studies are completed, claims about comprehensive multi-drug protocols necessarily remain more speculative than claims about the individual agents from which they are built.

The Protocols: Where Individual Evidence Gets Blurred Together

The discussion becomes more complicated when these drugs are combined into named cancer protocols. The most widely circulated examples include the Joe Tippens protocol, William Makis protocols, FLCCC or Independent Medical Alliance cancer guidance, and various orthomolecular or ISOM regimens. Although the details differ, most combine one or more antiparasitic drugs with supplements, dietary changes, metabolic therapies, or other repurposed medications.

The central problem is that evidence for an individual ingredient is often presented as evidence for the entire protocol. That is not how combination treatments are validated. Even when two or three components have some scientific support on their own, researchers still need to study the complete regimen to determine whether the combination is effective, whether the doses are appropriate, and whether the ingredients interact safely. None of the major named protocols reviewed here has been validated as a complete treatment regimen in a prospective controlled clinical trial.

The Joe Tippens protocol is built around fenbendazole, commonly combined with curcumin, CBD, and sometimes vitamin E. Tippens’ recovery is the main reason the regimen became widely known, but he was also receiving conventional cancer treatment, including immunotherapy. That makes it impossible to determine what role, if any, fenbendazole played in his remission. No independently audited patient group or controlled trial has established a success rate for the protocol.

William Makis and related orthomolecular protocols are generally more complex. They may combine ivermectin with mebendazole or fenbendazole, along with intravenous vitamin C, vitamin D, zinc, fasting, ketogenic diets, and other drugs or supplements. The supporting materials frequently cite laboratory studies or early research on individual components. What has not been produced is reliable clinical evidence showing that the complete combination improves tumor response or survival. The protocols also change over time, making it difficult to define exactly which version is being evaluated.

The same limitation applies to FLCCC or Independent Medical Alliance cancer guidance. These documents discuss multiple repurposed drugs and supplements, but they should be understood as proposed treatment frameworks rather than clinically validated cancer regimens. A scientific paper showing that one ingredient affects cancer cells does not prove that a larger mixture of drugs, supplements, and dietary interventions will benefit patients.

This does not mean every component is useless. Some may eventually prove valuable, and several are already being studied independently. It means the strength of the evidence must be described honestly. At present, the named protocols are supported mainly by biological theories, studies of individual ingredients, early human research, and personal reports—not by controlled trials of the complete regimens.

Why Scientists Disagree

One of the most confusing aspects of researching repurposed drugs for cancer is the enormous gap between the conclusions reached by different groups of experts. Depending on which articles, organizations, or physicians someone consults, they may encounter two completely different narratives.

One perspective argues that drugs such as ivermectin, fenbendazole, mebendazole, and albendazole represent some of the most promising developments in modern oncology but have been ignored because they are inexpensive, off-patent medications with little commercial value. Another perspective maintains that the excitement surrounding these drugs is driven primarily by laboratory findings, anecdotal reports, and confirmation bias rather than convincing clinical evidence.

Both perspectives draw upon real evidence.

The disagreement arises not because one side has access to entirely different facts, but because they assign different weight to different kinds of evidence.

Different Standards of Proof

Perhaps the single greatest source of disagreement concerns what should count as sufficient evidence.

Researchers working within evidence-based medicine generally regard randomized controlled trials as the most reliable method for determining whether a treatment improves patient outcomes. These studies are designed to minimize bias by comparing similar groups of patients, controlling for confounding factors, and measuring predefined clinical endpoints such as survival or progression-free survival.

Supporters of repurposed drugs often argue that this standard, while scientifically rigorous, creates a practical problem for inexpensive generic medications. Conducting large oncology trials is extraordinarily expensive, and because off-patent drugs cannot easily generate exclusive profits, pharmaceutical companies have little financial incentive to fund the studies needed for regulatory approval.

Both observations are true.

Randomized trials remain the strongest form of clinical evidence, and the financial incentives to perform those trials are often much weaker for generic medications than for newly patented drugs. Recognizing this tension helps explain why many repurposed drugs possess extensive laboratory research but relatively little high-quality clinical evidence.

Different Interpretations of Laboratory Research

Scientists also disagree about the significance of laboratory findings.

Researchers enthusiastic about repurposed drugs often point to hundreds of published studies demonstrating that these medications can inhibit cancer-cell growth, trigger apoptosis, interfere with signaling pathways, reduce metastasis in animal models, or enhance the effects of chemotherapy or immunotherapy.

More skeptical investigators acknowledge these findings but note that similar laboratory success has been observed for thousands of compounds that ultimately failed during human clinical trials.

History supports both perspectives.

Laboratory research is an essential first step in developing new therapies. Without it, no modern cancer treatment would exist. At the same time, most compounds that perform well in cell cultures or animal models never become successful cancer drugs because promising biological mechanisms do not always translate into meaningful clinical benefit.

The disagreement, therefore, is not over whether the laboratory research exists. It is over how much confidence those findings should inspire before human trials are completed.

The Role of Anecdotal Evidence

Individual patient stories are another major source of disagreement.

Many patients report remarkable recoveries after incorporating repurposed drugs into their treatment plans. Some describe unexpected remissions after exhausting conventional options. Others attribute long-term survival to protocols that include antiparasitic medications.

These accounts are compelling because they involve real people rather than abstract statistics.

However, physicians and clinical researchers generally caution against drawing conclusions from individual cases alone. Cancer outcomes vary widely between patients, and spontaneous remissions, delayed responses to previous treatments, differences in tumor biology, concurrent therapies, and simple statistical variation can all influence individual outcomes.

An anecdote can generate an important scientific hypothesis.

It cannot, by itself, establish causation.

This distinction sometimes creates frustration. Patients understandably focus on individual success stories because those stories represent hope. Researchers focus on controlled studies because those studies are designed to determine whether the same results can be expected across larger populations.

Publication Bias and Research Gaps

Another point of disagreement concerns what is not published.

Some advocates argue that potentially beneficial findings receive insufficient attention because there is little commercial incentive to pursue generic drugs. Others point to publication bias, in which positive studies are more likely to appear in journals than negative ones, potentially exaggerating the apparent promise of experimental therapies.

Both forms of bias can exist simultaneously.

Commercial incentives undoubtedly influence which drugs receive extensive clinical development. At the same time, scientific publishing has long struggled with the tendency to report positive findings more frequently than unsuccessful experiments. As a result, the published literature may both underrepresent certain therapies and overrepresent positive early findings.

Recognizing these competing biases is essential for interpreting the evidence objectively.

Social Media and Public Perception

Public understanding of repurposed drugs has increasingly been shaped by social media, podcasts, online communities, and video platforms rather than scientific journals.

These platforms have made medical research more accessible than ever before, allowing patients to read studies that would previously have remained largely within academic medicine. They have also enabled physicians, scientists, and patients to share information rapidly across the world.

At the same time, social media rewards certainty, simplicity, and emotionally compelling narratives.

Nuanced scientific discussions often perform poorly compared with confident declarations that a treatment either unquestionably works or unquestionably does not. As information spreads through repeated sharing, important qualifications can gradually disappear, leaving conclusions that sound far more definitive than the underlying evidence actually supports.

This dynamic has contributed substantially to the polarization surrounding repurposed drugs.

Regulatory Approval Is Not the Same as Scientific Truth

Another common misunderstanding involves the relationship between regulatory approval and scientific validity.

Approval by agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or comparable national regulators indicates that a treatment has met predefined standards for safety and effectiveness for a specific indication. It does not necessarily mean that every unapproved use is ineffective.

Conversely, lack of regulatory approval should not be interpreted as evidence that a treatment has been disproven.

Many therapies remain investigational simply because the necessary clinical trials have not yet been completed. Others ultimately fail because larger studies demonstrate that early promise does not translate into meaningful patient benefit.

Regulatory decisions therefore answer a different question than laboratory research.

Laboratory studies ask whether a treatment might work.

Clinical trials ask whether it actually helps patients.

Regulatory agencies decide whether the available evidence is sufficient to support routine medical use.

Confusing these separate questions contributes to much of the public debate.

Reasonable Scientists Can Reach Different Conclusions

Scientific disagreement is often portrayed as evidence that one side must be dishonest or uninformed.

In reality, researchers can examine the same body of evidence and reach different conclusions depending on how they weigh uncertainty, biological plausibility, clinical experience, and the quality of available data.

Some conclude that the laboratory evidence is sufficiently compelling to justify broader clinical use while additional trials are conducted.

Others believe the absence of convincing randomized clinical evidence warrants limiting these drugs to carefully monitored research settings.

Both positions reflect legitimate scientific priorities.

One emphasizes the urgency of offering potentially beneficial therapies to patients with limited options.

The other emphasizes the importance of avoiding treatments whose effectiveness has not yet been demonstrated.

Understanding these differing perspectives helps explain why discussions surrounding repurposed drugs have become so polarized. The disagreement is not simply about individual studies. It reflects fundamentally different judgments about how medical evidence should be interpreted when promising laboratory science has advanced more quickly than definitive clinical trials.

What Patients Should Know Before Considering Repurposed Antiparasitic Drugs

For patients facing a cancer diagnosis, it’s easy to understand why repurposed drugs have attracted so much interest. They are generally inexpensive, many have been used safely for years in their approved indications, and laboratory studies have produced results that appear promising. When conventional treatments have limited success or significant side effects, the idea that an existing medication might offer another option is understandably appealing.

At the same time, hope should not replace evidence. The fact that a drug is approved for one condition does not automatically make it safe or effective for another. Cancer patients often receive chemotherapy, immunotherapy, targeted drugs, steroids, anticoagulants, and numerous supportive medications. Adding repurposed drugs without medical supervision can increase the risk of drug interactions, unexpected side effects, or delays in receiving treatments that have already been proven to improve survival.

Another important consideration is product quality. Human-approved medications are manufactured under strict regulatory standards, while veterinary products are intended for animals and may differ in formulation, dosage, inactive ingredients, and quality-control requirements. For this reason, physicians and regulatory agencies generally advise against using veterinary medications in place of approved human pharmaceuticals, even when the active ingredient is chemically similar.

Patients should also be cautious when evaluating claims online. Testimonials, podcasts, videos, and social media posts often highlight dramatic success stories while rarely discussing patients who did not benefit or experienced complications. This phenomenon, known as survivorship bias, can create a misleading impression of effectiveness. Scientific studies attempt to reduce this bias by following all participants—not just the success stories—and by comparing outcomes with similar patients who did not receive the experimental treatment.

For individuals interested in repurposed drugs, one of the safest approaches is to discuss the available evidence with their oncology team and ask whether any legitimate clinical trials may be appropriate. Clinical trials provide careful monitoring, standardized dosing, and the opportunity to answer the very questions that patients and researchers alike are trying to resolve. Participating in well-designed research not only helps individual patients but also contributes to the evidence that will determine whether these drugs ultimately become part of future cancer treatment.

The Biggest Scientific Questions Still Unanswered

The debate over repurposed antiparasitic drugs cannot be resolved by counting laboratory studies, collecting testimonials, or pointing to the number of biological pathways a drug may affect. The central questions are clinical: Which patients, if any, benefit? At what dose? In which cancers? In what combinations? And with what risks?

Until those questions are answered through carefully designed human studies, the evidence will remain incomplete.

Can Effective Concentrations Be Reached Safely in Humans?

One of the most important unresolved issues is whether the drug concentrations that affect cancer cells in laboratory experiments can be achieved safely in people.

Cell-culture studies often expose cancer cells directly to concentrations that may be difficult to reproduce in human blood or tumor tissue. The difference can be substantial. A drug may appear highly active in a laboratory dish while producing only a fraction of that exposure when taken orally at conventional doses.

This does not automatically invalidate the laboratory findings. Blood concentration is not the only relevant measurement. Some drugs accumulate in particular tissues, produce active metabolites, or exert effects through immune and metabolic pathways that are not fully captured by standard pharmacokinetic comparisons.

Even so, the concentration gap remains a major scientific obstacle. Researchers need better studies measuring how much ivermectin, fenbendazole, mebendazole, albendazole, and their metabolites actually reach human tumors at tolerable doses.

Which Cancers Are Most Likely to Respond?

Cancer is not one disease.

Breast cancer, pancreatic cancer, melanoma, leukemia, and glioblastoma differ profoundly in their genetics, metabolism, immune environment, growth patterns, and response to treatment. Even tumors arising in the same organ may behave very differently depending on their molecular subtype.

Laboratory studies have reported activity across many cancer models, but that breadth can create a misleading impression of universal effectiveness. A drug that interferes with one pathway may be relevant only to tumors that depend heavily on that pathway.

Future research must identify predictive biomarkers—measurable characteristics that indicate which tumors are most likely to respond. Without biomarkers, clinical trials may combine patients with biologically different cancers and obscure a benefit that exists only in a narrow subgroup.

Do These Drugs Work Alone or Only in Combination?

Most proposed uses of repurposed antiparasitic drugs involve combinations.

Ivermectin may be paired with immunotherapy. Mebendazole may be added to chemotherapy or radiation. Fenbendazole is commonly promoted alongside vitamins, supplements, metabolic interventions, and conventional cancer treatment.

This raises a critical question: Is the repurposed drug independently active, or does it merely alter the effects of another therapy?

A drug might have little value by itself but become useful as a sensitizer that makes tumors more vulnerable to chemotherapy, radiation, or immune attack. Conversely, it might interfere with a standard treatment or add toxicity without increasing effectiveness.

Properly designed combination trials must include comparison groups capable of separating the effect of the experimental drug from the effects of the treatments patients are already receiving.

What Is the Appropriate Dose?

The doses used for parasitic infections were not developed for cancer treatment.

Cancer protocols circulating online frequently recommend higher doses, longer treatment periods, intermittent schedules, or combinations that have not been systematically studied. In some cases, the recommended amounts are extrapolated from animal studies or individual physician experience rather than formal dose-escalation trials.

The most effective cancer dose, if one exists, may not be the highest tolerable dose. Some proposed mechanisms could require continuous exposure, while others might depend on brief pulses. Dosing may also differ according to tumor type, liver function, body composition, genetic factors, and concurrent medications.

Early-phase clinical trials are needed to define:

• the maximum tolerated dose;
• the biologically active dose;
• the most effective schedule;
• the effects of long-term administration;
• and the relationship between blood levels, tumor exposure, and clinical response.

Without this information, dosing recommendations remain uncertain.

How Do Formulation and Absorption Affect the Results?

Several of these drugs have limited or variable absorption.

Fenbendazole was developed primarily for veterinary use and lacks a standardized human cancer formulation. Mebendazole and albendazole can produce variable blood concentrations depending on the formulation, food intake, metabolism, and individual patient factors. Ivermectin absorption may also change when taken with food, but increasing absorption can alter both potential activity and toxicity.

Researchers are exploring improved formulations, including nanoparticles, lipid-based delivery systems, and other approaches designed to increase tumor exposure. These technologies may eventually make some laboratory findings more clinically relevant.

However, a reformulated drug is not necessarily equivalent to the original medication. Changes that improve absorption may also change distribution, metabolism, side effects, and drug interactions. Each formulation requires its own testing.

Can Resistance Develop?

Cancer cells adapt.

Even highly effective targeted therapies frequently lose effectiveness as tumors acquire new mutations, activate alternative pathways, or alter drug transport. Repurposed antiparasitic drugs would not be exempt from this problem.

If these medications eventually demonstrate clinical activity, researchers will need to determine how quickly resistance develops and which biological changes drive it. Understanding resistance could help identify rational combinations and prevent patients from remaining on ineffective treatment after their disease has adapted.

How Do These Drugs Interact with Standard Cancer Treatments?

Patients considering repurposed drugs are often already receiving chemotherapy, immunotherapy, radiation, hormone therapy, targeted therapy, surgery-related medications, or supportive treatments.

Potential interactions may occur at several levels.

A repurposed drug could alter liver enzymes responsible for metabolizing another medication. It could increase or decrease blood concentrations of chemotherapy. It might intensify liver toxicity, affect bone marrow function, influence bleeding risk, or change immune activity.

Interactions may also be beneficial. Some laboratory studies suggest that antiparasitic drugs could sensitize tumors to radiation, chemotherapy, or checkpoint inhibitors. That possibility is one of the strongest arguments for continued research.

The direction of an interaction cannot be assumed. A combination that appears logical based on mechanism may prove ineffective or unsafe in patients. Formal interaction studies are necessary.

What Are the Risks of Long-Term Use?

The safety records of these medications are based largely on their approved indications.

A short course used to treat a parasitic infection does not provide the same safety information as months or years of cancer-directed treatment. Long-term use may produce cumulative liver injury, neurologic effects, blood-count abnormalities, gastrointestinal complications, or interactions that would rarely emerge during brief treatment.

Cancer patients may also be more vulnerable than otherwise healthy individuals. They may have impaired liver or kidney function, low blood counts, poor nutritional status, extensive tumor burden, or previous treatment-related organ damage.

Long-term safety must therefore be evaluated specifically in oncology populations rather than inferred entirely from antiparasitic use.

Are Veterinary and Human Products Clinically Equivalent?

Fenbendazole presents a distinctive challenge because it is primarily a veterinary drug.

Animal formulations may contain different concentrations, inactive ingredients, manufacturing standards, and quality controls than medications intended for human use. Products sold for livestock or pets are not automatically appropriate for human dosing.

Even when the active ingredient is chemically identical, the absence of an approved human formulation creates uncertainty about purity, consistency, absorption, and contamination. Reliable clinical research would require pharmaceutical-grade material manufactured specifically for human investigation.

Which Outcomes Should Trials Measure?

Tumor shrinkage is not the only meaningful outcome in cancer treatment.

A therapy may stabilize disease without producing dramatic shrinkage. It may delay progression, improve symptoms, reduce treatment toxicity, or increase quality of life. Conversely, a temporary reduction in tumor size may not lead to longer survival.

Trials must therefore distinguish among:

• tumor response;
• progression-free survival;
• overall survival;
• symptom control;
• treatment tolerance;
• quality of life;
• and durable remission.

Public discussions often focus on scans or tumor markers from individual patients. Those observations may be important, but they do not necessarily reveal whether a treatment improves long-term outcomes.

How Can Anecdotal Successes Be Studied Properly?

Patient stories should neither be treated as proof nor dismissed automatically.

Some of the most important discoveries in medicine began with an unexpected clinical observation. The appropriate response to a credible anecdote is not immediate acceptance or ridicule. It is systematic investigation.

Researchers could strengthen this process by collecting standardized information on diagnosis, pathology, molecular subtype, previous treatments, exact dosing, concurrent therapies, imaging, laboratory results, adverse events, and long-term follow-up.

When reports lack those details, it becomes nearly impossible to determine what happened or whether the outcome can be reproduced. Well-documented case series could help generate hypotheses and identify patient groups for future trials, even though they would not replace controlled studies.

Who Will Fund the Necessary Trials?

Perhaps the most practical unanswered question is who will pay for definitive research.

Large cancer trials are expensive. Off-patent medications generally offer limited opportunities for market exclusivity, reducing the incentive for commercial sponsors to invest in them. This does not prove that effective generic treatments are being deliberately suppressed, but it does create a genuine structural disadvantage.

Potential solutions include government funding, nonprofit research organizations, academic collaborations, philanthropic support, public-private partnerships, and innovative trial designs that reduce cost.

Repurposed drugs will remain trapped between laboratory promise and public controversy unless institutions are willing to fund the studies capable of producing clear answers.

What Evidence Would Settle the Debate?

No single experiment will resolve every question.

The strongest research program would proceed in stages:

First, pharmacokinetic studies would determine whether biologically relevant tumor exposure can be achieved safely.

Next, early-phase trials would establish dosing, identify toxicities, and explore biomarkers.

Randomized trials would then compare standard treatment with and without the repurposed drug in clearly defined cancer populations.

Independent replication would be essential, particularly when initial results appear unusually positive.

The evidence should also include transparent reporting of negative results. Failed trials are scientifically valuable because they identify ineffective doses, combinations, and cancer types, allowing future research to become more precise.

The ultimate question is not whether these drugs are inexpensive, controversial, heavily studied in laboratories, or supported by compelling testimonials.

It is whether they help patients live longer or live better with an acceptable level of risk.

That question remains open.

Conclusion: Following the Evidence Wherever It Leads

The idea that existing antiparasitic drugs might one day play a role in cancer treatment is neither implausible nor unprecedented. Drug repurposing has produced important medical advances in the past, and researchers continue to investigate whether medications such as ivermectin, fenbendazole, mebendazole, and albendazole have properties that could benefit cancer patients. Laboratory studies have identified several biological mechanisms worth exploring, and early human trials—particularly with mebendazole—suggest that additional research is justified.

At the same time, the current evidence does not support the broad claims often made online. None of these drugs has been proven in randomized clinical trials to cure cancer or to improve survival across multiple cancer types. Some of the most widely cited studies have been questioned or retracted, while many of the strongest claims continue to rely on laboratory experiments, anecdotal reports, or observational research that cannot establish cause and effect.

That does not mean these drugs have been disproven. It means the most important questions remain unanswered. Researchers are still working to determine which cancers, if any, might respond to these medications, what doses are appropriate, whether combinations with standard therapies offer additional benefit, and which patients might be most likely to respond. These are precisely the questions that well-designed clinical trials are intended to answer.

Cancer patients deserve accurate information—not exaggerated promises, but not premature dismissal either. The most scientifically responsible position is to recognize both the potential and the limitations of the current evidence. Curiosity should encourage research. Hope should inspire better clinical trials. But treatment decisions should remain grounded in the strongest evidence available.

As research continues, some of these drugs may ultimately prove to have a place in oncology, while others may not. Until then, the evidence supports cautious optimism, rigorous investigation, and an unwavering commitment to separating what is known from what is merely hoped for.

---

Appendix A: Current Human Clinical Studies

Drug	Cancer Type	Study Type	Status	Search Terms
Ivermectin	Triple-negative breast cancer	Phase I/II	Recruiting	“ivermectin breast cancer clinical trial ClinicalTrials.gov”
Ivermectin	Solid tumors	Phase II	Planned/Not yet recruiting	“ivermectin cancer ClinicalTrials.gov”
Mebendazole	High-grade glioma	Phase I	Completed	“mebendazole glioma Phase I”
Mebendazole	Metastatic colorectal cancer	Randomized pilot	Completed	“mebendazole colorectal cancer trial”
Albendazole	Advanced solid tumors	Phase I	Completed	“albendazole cancer Phase I”
Fenbendazole	Human cancer	Interventional trials	None identified	“fenbendazole cancer ClinicalTrials.gov”

The easiest places to search are:

• ClinicalTrials.gov
• PubMed
• Google Scholar

---

Appendix B: Drug Profiles

Give each drug its own quick-reference box.

Ivermectin

• FDA-approved for humans: Yes
• Veterinary use: Yes
• Human cancer trials: Yes (early phase)
• Randomized evidence: None showing effectiveness
• Overall evidence: Laboratory studies + early human research

---

Fenbendazole

• FDA-approved for humans: No
• Veterinary use: Yes
• Human cancer trials: None
• Randomized evidence: None
• Overall evidence: Laboratory studies and anecdotal reports

---

Mebendazole

• FDA-approved for humans: Yes
• Human cancer trials: Multiple early-phase studies
• Randomized evidence: Limited
• Overall evidence: Strongest human evidence among these four drugs

---

Albendazole

• FDA-approved for humans: Yes
• Human cancer trials: Early Phase I studies
• Randomized evidence: None
• Overall evidence: Limited but legitimate clinical research

---

Appendix C: Frequently Asked Questions

Questions like:

• Has any antiparasitic drug been proven to cure cancer?
• Why do laboratory studies often fail in humans?
• What’s the difference between Phase I, II, and III trials?
• Why are testimonials considered weak evidence?
• Why are veterinary drugs different from human medications?
• Should patients stop conventional treatment to try these drugs?
• How can I tell whether a study is reliable?

---

Appendix D: Evidence Timeline

A simple chronology:

• 2000s – First laboratory studies
• 2010–2018 – Expansion of animal research
• 2019–2022 – Early human mebendazole trials
• 2023–2026 – Ivermectin Phase I/II studies
• 2026 – Editorial Expressions of Concern and retractions published

This helps readers understand how the evidence has evolved.

---

References

I would also include a full reference section divided by category instead of one long bibliography.

For example:

Systematic Reviews

• Systematic reviews of ivermectin and cancer
• Systematic reviews of mebendazole
• Reviews of benzimidazoles

Clinical Trials

• Phase I albendazole studies
• Phase I mebendazole glioma studies
• Randomized colorectal trial
• Ivermectin breast cancer trial

Case Reports

• Fenbendazole-associated liver injury
• Ivermectin-associated liver injury
• Published case reports

Observational Studies

• 2026 ivermectin/mebendazole cohort

Retracted or Questioned Papers

• Fenbendazole case-series (retracted)
• 2021 ivermectin immunotherapy paper (Expression of Concern)

---